The use of hydroxychloroquine (HCQ) in Primary Sjögren’s Syndrome (pSS) has been assessed in different studies over the last years, with conflicting results regarding its efficacy in sicca syndrome and extraglandular manifestations (EGM). The goal of this study was to compare the incidence rate of EGM in pSS patients with and without HCQ therapy.
We performed a multicenter retrospective study, including patients with pSS (European classification criteria) with at least 1 year of follow-up. Subjects with concomitant fibromyalgia, autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis were excluded. Demographics and pSS characteristics were recorded. The EGM were defined by EULAR-SS disease activity index (ESSDAI). Patients were divided into two groups according to their use or not of HCQ therapy. We evaluated the use of HCQ and its relationship to EGM. HCQ therapy was defined as the continuous use of the drug for at least 3 months. A descriptive analysis of demographics and pSS characteristics was performed. We compared the incidence of EGM between groups defined by HCQ therapy using chi2 test or Fisher’s exact test. A total of 221 patients were included (97.3% women), mean age, 55.7 years (SD 14). Mean age at diagnosis, 48.8 years (SD 15); median disease duration, 60 months (IQR 35–84). One hundred and seventy patients (77%) received HCQ. About half of the patients had at least one EGM during the course of the disease, 20% of them developed an EGM before the onset of the sicca syndrome and 26% simultaneously with dryness symptom. Overall, EGM were less frequent in those on HCQ therapy (36.5% vs 63.5%, p < 0.001). Considering each EGM individually, the following manifestations were more frequent in the non-treated group: arthritis (p < 0.001), fatigue (p < 0.001), purpura (p = 0.01), Raynaud phenomenon (p = 0.003), and hypergammaglobulinemia (p = 0.006). Immunosuppressive treatment was indicated on 28 patients (12.7%), 13 of which were receiving also HCQ. The first reason for those treatments was the presence of arthritis in 12/28 patients (42.8%), and the drug used in all the cases was methotrexate. Only three patients required immunosuppressive therapy with cyclophosphamide, due to the presence of glomerulonephritis, vasculitis, and interstitial lung disease. None of the patients received biologic therapy. The lower incidence of EGM was observed in patients on HCQ therapy supports its efficacy in pSS. However, further large scale prospective studies are needed to confirm these findings.
This is a preview of subscription content, access via your institution.
Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X (2012) Primary Sjögren syndrome. BMJ 344. https://doi.org/10.1136/bmj.e3821
Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331. https://doi.org/10.1016/S0140-6736(05)66990-5
Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Ramos-Casals M (2013) Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother 14:279–289. https://doi.org/10.1517/14656566.2013.767333
Mavragani CP, Moutsopoulos NM, Moutsopoulos HM (2006) The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol 2:252–261. https://doi.org/10.1038/ncprheum0165
Ter Borg EJ, Kelder JC (2016) Polyarthritis in primary Sjögren’s syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up. Clin Rheumatol 35:649–655. https://doi.org/10.1007/s10067-016-3175-3
Scagliusi P, Minenna G, D’Amore M, Scagliusi A (2005) New therapeutic perspectives in Sjögren syndrome: leflunomide. Recenti Prog Med 96:194
Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E (2016) A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren’s syndrome. Clin Rhreumatol 35:2203–2210. https://doi.org/10.1007/s10067-016-3360-4
Patel R, Shahane A (2014) The epidemiology of Sjögren’s syndrome. Clin Epidemiol 6:247–255. https://doi.org/10.2147/CLEP.S47399
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG (2012) Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol 8:399–411. https://doi.org/10.1038/nrrheum.2012.53
Gottenberg JE, Ravaud P, Puéchal X, Le Guern V et al (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312:249–258. https://doi.org/10.1001/jama.2014.7682
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
The Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150–154
Wallace D (1994) Antimalarial agents and lupus. Rheum Dis Clin N Am 20:243–263
Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317
Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, González EB, Dang N, Papalardo E, Liu J, Vilá LM, Reveille JD, Alarcón GS, Pierangeli SS (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21:830–835. https://doi.org/10.1177/0961203312437270
Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW (1993) Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 52:360–364
Yoon CH, Lee HJ, Lee EY, Lee EB, Lee WW, Kim MK, Wee WR (2016) Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren’s syndrome: a double-blind randomized control study. J Korean Med Sci 31:1127–1135. https://doi.org/10.3346/jkms.2016.31.7.1127
Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV (1988) Treatment of primary Sjögren’s syndrome with hydroxychloroquine. Am J Med 85:62–67
Fox R, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 1):S31–S36
Tishler M, Yaron I, Shirazi I, Yaron M (1999) Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58:253–256
Yavuz S, Asfuroğlu E, Bicakcigil M, Toker E (2011) Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren’s syndrome. Rheumatol Int 31:1045–1049. https://doi.org/10.1007/s00296-010-1415-4
Wang SQ, Zhang LW, Wei P, Hua H (2017) Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis. BMC Musculoskeletal Disord 18:186. https://doi.org/10.1186/s12891-017-1543-z
Zazzetti F, Rivero M, Duartes Noe DE, Gallacher A, Schiel A, Khoury MC, Laborde HA, Barreira JC (2010) Frequency of systemic manifestations in patients with primary Sjogren’s syndrome in Argentina. Reumatol Clin 6:299–302. https://doi.org/10.1016/j.reuma.2010.01.004
Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A et al (2014) Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients. Rheumatology (Oxford) 53:321–331. https://doi.org/10.1093/rheumatology/ket349
Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman S et al (2015) Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 54:2230–2238. https://doi.org/10.1093/rheumatology/kev200
Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S et al (2016) Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12:137–156. https://doi.org/10.1586/1744666X.2016.1109449
Conflicts of interest
The following authors have declared conflicts of interest:
Rafael Chaparro del Moral is Biotherapeutics Medical Manager at AbbVie.
Federico Zazzetti is Immunology Medical Manager at Janssen.
Sofía Velez is Senior Medical Science Liaison at Janssen.
The other remaining authors declare no conflicts of interest.
The study was approved by the institutional review board or ethics committee at each participating site and was conducted in accordance with the principles of the Declaration of Helsinki.
Statement of informed consent
All patients provided written informed consent.
About this article
Cite this article
Demarchi, J., Papasidero, S., Medina, M.A. et al. Primary Sjögren’s syndrome: Extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol 36, 2455–2460 (2017). https://doi.org/10.1007/s10067-017-3822-3
- Extraglandular manifestations
- Primary Sjögren’s syndrome